A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Trametinib (Primary) ; Iodine-124; Iodine-131
- Indications Follicular lymphoma; Papilloma; Thyroid cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 12 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2018.
- 12 Apr 2016 Status changed from suspended to recruiting.